Physician profile
Albert Coo
NPI 1336160837
$16,817.80
in general payments reported to CMS, 2019-2025
61 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,181 · 2020: $2,524 · 2021: $2,017 · 2022: $1,967 · 2023: $2,100 · 2024: $1,878 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,074 · Education: $55.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,074.09 |
| Education | $55.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $4,639.88 | 2019-2025 | Korlym |
| Lilly USA, LLC | $1,806.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $1,332.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,086.22 | 2019-2025 | |
| Abbvie INC. | $844.66 | 2019-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $843.41 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $565.02 | 2019-2025 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $421.46 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $384.16 | 2019-2023 | Steglatro, Verquvo, Belsomra |
| Mannkind Corporation | $295.17 | 2020-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.37 | 2019-2025 | Jardiance |
| Medtronic, INC. | $247.80 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Amarin Pharma, INC. | $224.41 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $218.74 | 2021-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $195.10 | 2024-2025 | Tepezza, Evenity |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $178.84 | 2019-2024 | Omnipod |
| Alexion Pharmaceuticals, INC. | $175.30 | 2023-2025 | Strensiq |
| Radius Health, INC. | $171.19 | 2023-2025 | Tymlos |
| Echosens North America, INC. | $159.60 | 2023 | Fibroscan |
| Viiv Healthcare Company | $154.49 | 2019-2020 | |
| Beta Bionics, INC. | $154.06 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Astrazeneca Pharmaceuticals Lp | $150.15 | 2019-2023 | Farxiga |
| Ibsa Pharma INC. | $147.04 | 2019-2024 | Licart, Tirosint |
| Abbott Laboratories | $145.29 | 2021-2024 | Freestyle Libre 3 |
| Acella Pharmaceuticals, LLC | $143.04 | 2022-2025 | NP Thyroid 60 |
| Novartis Pharmaceuticals Corporation | $119.15 | 2022-2023 | |
| Kyowa Kirin, INC. | $109.21 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $99.37 | 2025 | Yorvipath |
| Gilead Sciences, INC. | $94.05 | 2020-2023 | |
| Janssen Pharmaceuticals, INC | $84.83 | 2019-2020 | |
| Dexcom, INC. | $83.11 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Antares Pharma, INC. | $82.60 | 2020-2025 | Xyosted |
| Madrigal Pharmaceuticals | $76.33 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $74.96 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $70.66 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sequel Med Tech, LLC | $66.09 | 2025 | Twiist |
| Tolmar, INC. | $64.44 | 2023-2025 | Jatenzo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.13 | 2019-2020 | |
| Pfizer INC. | $63.95 | 2019-2023 | |
| Shire North American Group INC | $63.74 | 2019 | |
| Lifescan, INC. | $61.24 | 2019-2021 | |
| Eusa Pharma (US) LLC | $55.95 | 2022 | |
| Currax Pharmaceuticals LLC | $53.42 | 2021-2023 | Nexletol |
| Embecta Corp. | $53.32 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Zealand Pharma US, INC. | $47.95 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $47.19 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $43.78 | 2023 | Adthyza |
| Kowa Pharmaceuticals America, INC. | $41.79 | 2020-2021 | |
| Medtronic Minimed, INC. | $40.07 | 2020 | |
| Clarus Therapeutics INC. | $29.08 | 2021 | |
| Theratechnologies INC. | $23.84 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.01 | 2023 | |
| Almatica Pharma LLC | $20.72 | 2025 | Teriparatide |
| Horizon Therapeutics Plc | $20.45 | 2023 | Tepezza |
| Intuity Medical INC | $18.02 | 2022 | |
| Companion Medical, INC. | $16.64 | 2019 | |
| Valeritas, INC. | $15.63 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.24 | 2022 | |
| Avion Pharmaceuticals | $14.66 | 2024 | NP Thyroid 60 |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
| Esperion Therapeutics, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Coo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.